Novo Nordisk has launched its blockbuster drug Ozempic in India, marking a significant moment in the country’s diabetes and weight-management landscape. Priced from Rs 8,800 per month, the once-weekly injectable medication is expected to draw wide attention from both clinicians and patients, given its global reputation and growing demand for advanced metabolic therapies.
Ozempic, whose active ingredient is semaglutide, has been approved in India for adults with uncontrolled type 2 diabetes, to be used alongside diet and exercise. The drug belongs to a class of medicines known as GLP-1 receptor agonists, which work by mimicking a natural hormone that helps regulate blood sugar levels and appetite. While officially approved for diabetes management, Ozempic is widely known for its weight-loss benefits, which have fuelled its popularity worldwide.
The medication is available in three dosage strengths—0.25 mg, 0.5 mg, and 1 mg—administered through a single-use, pre-filled pen designed for subcutaneous injection. Each pen contains four weekly doses, making it a once-a-week treatment. The initial 0.25 mg dose is priced at Rs 8,800 for four weeks, with the 0.5 mg dose costing Rs 10,170 and the 1 mg dose priced at Rs 11,175.
Novo Nordisk said the pen device, known as Novofine Needles, has been designed for ease of use and minimal discomfort, an important factor for patients who may be apprehensive about injectable therapies. The once-weekly dosing schedule is also expected to improve treatment adherence compared to daily medications.
Company officials described the launch as a major milestone. Vikrant Shrotriya, Managing Director of Novo Nordisk India, said Ozempic brings together global clinical evidence, established quality standards, and a robust supply chain to offer doctors an effective treatment option. He added that the therapy aims not only to improve glycaemic control but also to support meaningful weight management and provide long-term protection for the heart and kidneys.
Globally, Ozempic was first approved by the US Food and Drug Administration in 2017 for type 2 diabetes. Over the years, it has gained enormous attention for its appetite-suppressing effects, leading to widespread off-label use for weight loss. Clinical studies have also shown that semaglutide can reduce the risk of major cardiovascular events and slow the progression of kidney disease in people with diabetes.
According to Novo Nordisk, Ozempic helps lower HbA1c levels, a key marker of long-term blood glucose control, while also acting on appetite centres in the brain to reduce hunger and food intake. This dual action addresses two major challenges faced by people with type 2 diabetes: poor glycaemic control and excess weight.
The launch comes at a time when the burden of type 2 diabetes continues to rise, increasing the need for therapies that go beyond sugar control to address broader metabolic and cardiovascular risks. With Ozempic’s entry, doctors now have access to a globally established option that combines diabetes management, weight reduction, and organ protection in a single, once-weekly treatment.
